Atea Pharmaceuticals
AVIR
81 hedge funds and large institutions have $3.04B invested in Atea Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 24 increasing their positions, 25 reducing their positions, and 7 closing their positions.
171% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 7
83% more call options, than puts
Call options by funds: $2.04M | Put options by funds: $1.12M
47% more capital invested
Capital invested by funds: $2.07B → $3.04B (+$970M)
17% more funds holding
Funds holding: 69 → 81 (+12)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0.57% less ownership
Funds ownership: 60.41% → 59.84% (-0.57%)
4% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$291M |
| 2 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$5.25M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$4.76M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.18M |
| 5 |
E
Ergoteles
New York
|
+$3.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AICPI
ABG Innovation Capital Partners III
Central, Hong Kong,
Hong Kong
|
-$110M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$72.5M |
| 3 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
-$16.9M |
| 4 |
BlackRock
New York
|
-$16.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$11.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
APA
76
American Portfolios Advisors
Holbrook,
New York
| $6.17K | -$7.09K | -105 | -51% |
|
|
LSA
77
Leonteq Securities AG
Zurich,
Switzerland
| $6.17K | +$6.76K | +100 | New |
|
|
IAIM
78
International Assets Investment Management
Orlando,
Florida
| $4K | – | – | – |
|
|
TWA
79
TCI Wealth Advisors
Tucson,
Arizona
| $2K | +$2.03K | +30 | New |
|
|
AIG
80
American International Group
New York
| $522 | +$1.55K | +23 | +0.3% |
|
|
AICPI
81
ABG Innovation Capital Partners III
Central, Hong Kong,
Hong Kong
| – | -$110M | -2,639,178 | Closed |
|
|
HA
82
HHLR Advisors
Grand Cayman,
Cayman Islands
| – | -$5.22M | -125,000 | Closed |
|
83
Alyeska Investment Group
Chicago,
Illinois
| – | -$3.13M | -75,000 | Closed |
|
|
CCM
84
CAAS Capital Management
New York
| – | -$2.92M | -70,000 | Closed |
|
|
MWNA
85
Marshall Wace North America
New York
| – | -$1.75M | -42,002 | Closed |
|
86
Norges Bank
Oslo,
Norway
| – | -$1.25M | -30,000 | Closed |
|
|
BI
87
Bramshill Investments
Naples,
Florida
| – | -$310K | -7,416 | Closed |
|
88
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | +$270 | +4 | New |
|
AVIR Hedge Fund Activity: Q1 2021 in Review
81 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q1 2021, worth a combined $3.04B — up 47% from $2.07B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AVIR positions and 7 closed out — a net gain of 12 holders — while 24 added to existing stakes and 25 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $291M. The largest seller was ABG Innovation Capital Partners III, exiting entirely with an estimated $110M sold.
- 81 institutional investors held Atea Pharmaceuticals (AVIR) as of Q1 2021, up from 69 in Q4 2020.
- Funds reported $3.04B of Atea Pharmaceuticals stock for Q1 2021, up 47% quarter-over-quarter.
- 19 funds opened new Atea Pharmaceuticals positions in Q1 2021 and 7 closed out, a net change of +12 holders.
- The largest Atea Pharmaceuticals buyer in Q1 2021 was Fidelity Investments, an estimated $291M added.
- The largest Atea Pharmaceuticals seller in Q1 2021 was ABG Innovation Capital Partners III, an estimated $110M sold.
Based on aggregated 13F filings for Q1 2021.